Viewing all links from the source for category: Pharma/Biotech

15/05/2026

Lumos Diagnostics: FebriDx paediatric study 250 patient enrolment milestone achieved

Oncosil: OSPREY registry interim results presented at ESGE Days 2026

14/05/2026

Clarity receives $9.8 million R&D tax incentive refund

13/05/2026

Imugene: Research as a Service (RaaS)

Medicines Australia: BUDGET IGNORES LIFE-CHANGING NEW AND FUTURE MEDICINES DESPITE GLOBAL CHALLENGES

11/05/2026

Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy

Perth medtech companies to take centre stage at AusMedtech

CSL: Interim CEO 90 Day Review and Financial Update

08/05/2026

Lumos receives milestone payment of USD$500,000 from BARDA for achieving Febrix CLIA waiver

AMPLIA THERAPEUTICS AND AUSTRALIA NEW ZEALAND GYNAECOLOGICAL ONCOLOGY GROUP (ANZGOG) ANNOUNCE OVARIAN CANCER STUDY

07/05/2026

Neuren Pharmaceuticals: Q1 2026 DAYBUE® net sales US$101m, up 20% from Q1 2025

06/05/2026

Noxopharm progresses US regulatory strategy

04/05/2026

AdAlta: Strategic placement raises A$2.5 million to advance BZDS1901 CAR-T therapy

01/05/2026

Telix and Regeneron Announce Strategic Radiopharma Collaboration

Noxopharm: New data shows SOF-SKN™ active ingredient efficacy in patient samples

LTR Pharma: SPONTAN®Phase IIinterim datademonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026

Telix: TLX101-Px (Pixlumi®) MAA Accepted in Europe

30/04/2026

Avecho Quarterly Activities Report and Appendix 4C

Clarity Pharmaceuticals: QUARTERLY ACTIVITY REPORT

Artrya: QUARTERLY ACTIVITIES & CASHFLOW REPORT QUARTER ENDED 31 MARCH 2026

Alterity Therapeutics: Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update

Little Green Pharma: QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C

Percheron Therapeutics: QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C

AVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GO

Mayne Pharma: FURTHER DETAILS REGARDING EQUITY INSTRUMENTS TO BE ISSUED TO THE CEO

Starpharma: Quarterly Activities Report & Appendix 4C

Telix: OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer

29/04/2026

Starpharma: Quarterly Activities Report & Appendix 4C

Botanix Pharmaceuticals Quarterly Activity Report and 4C Quarterly Cash Flow Report Q3 FY26

MAYNE PHARMA REPORTS UNAUDITED 3Q FY26 RESULTS

AdAlta: BZDS1901 manufacturing agreement

Emyria Extends National Expansion into New South Wales

AMSANT urges early presentation and vaccination as diphtheria outbreak grows – Aboriginal Medical Services Alliance Northern Territory

PYC Therapeutics: Q1 2026 SHAREHOLDER UPDATE

PYC Therapeutics: ORPHAN DRUG DESIGNATION GRANTED FOR RP11 DRUG CANDIDATE BY EUROPEAN MEDICINES AGENCY

Syntara: Amsulostat poised for late-stage clinical development following positive FDA feedback

28/04/2026

Orthocell: Remplir RWE study delivers 90% success rate

Amplia: QUARTERLY ACTIVITIES AND CASH FLOW REPORTS – March 2026

EMYRIA’S NATIONAL SCALE AND CLINICAL VALIDATION ACCELERATE

LTR Pharma: Quarterly Activities Report & Appendix 4C

INOVIQ: OVARIAN CANCER TEST CLINICAL STUDY ON TRACK AND LAB PARTNER NEGOTIATIONS ADVANCING

Noxopharm: Innovative collaboration further expands Sofra™ platform

Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy

Clinuvel: FDA relaxes SCENESSE® postmarketing requirement

24/04/2026

Noxopharm: March 2026 Quarterly Activities Report and Appendix 4C

23/04/2026

RADIOPHARM THERANOSTICS: Quarterly Activities & Cash Report and 4C for the quarter ended 31 March 2026

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

20/04/2026

Orthocell reports continued growth and strong US momentum in March 2026 quarter

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026